Pembrolizumab biosimilar (Celltrion)

帕博利珠单抗生物类似药（Celltrion）

Report date: 2024/08/13 17:14:51

Base Information

Drug NamePembrolizumab biosimilar (Celltrion)
Drug Alias NameCT-P51
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGeorgiaSouth Korea
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A